StockData
Korsana Biosciences, Inc. logo

Korsana Biosciences, Inc. (KRSA) shareholders

KRSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30493% above fair value
$32.50−0.18 (-0.55%)

Close on Nov 17, 2026Market cap $152.14MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
15.1%
1M of 5M shares
Institutional holders
21
9 new, 5 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Tomas Kiselak
Joint filing with Fairmount Funds Management LLC (19.99%), Peter Evan Harwin (19.99%) and 1 more
9,106,42019.99%13D (active)Sep 8, 2026
Nimish Shah
Joint filing with Venrock Healthcare Capital Partners III, L.P. (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 6 more
4,552,2779.90%13D (active)Sep 8, 2026
General Atlantic, L.P.
Joint filing with General Atlantic Partners 100, L.P. (6.80%), GAP Coinvestments III, LLC (6.80%) and 14 more
3,201,1316.80%13G (passive)Sep 8, 2026
Abigail P. Johnson
Joint filing with FMR LLC (6.90%)
3,144,7976.90%13G (passive) amendmentSep 30, 2026
Wellington Biomedical Innovation Master Investors (Cayman) II, L.P.2,775,7886.10%13G (passive)Sep 9, 2026
JPMorgan Chase & Co.2,687,9145.90%13G (passive)Sep 30, 2026
Peter M. Hecht910,24019.40%13D (active) amendmentJul 16, 2026
Bam Gp LLC
Joint filing with Balyasny Asset Management L.P. (7.33%), Balyasny Asset Management Holdings LP (7.33%) and 2 more
317,5117.33%13G (passive)Jun 30, 2026
ADAR1 Capital Management, LLC
Joint filing with Daniel Schneeberger (7.00%)
298,7577.00%13G (passive)Jun 30, 2026
J. Wood Capital Advisors LLC
Joint filing with Jason Wood (5.40%)
181,8185.40%13G (passive)Mar 25, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of KRSAValueChange% of portfolio
Kalehua Capital Management LLC471,81410.08%$11.20MNew3.57%
FMR LLC92,7931.98%$2.20M+92,1160.00%
Balyasny Asset Management L.P.45,3590.97%$1.08MNew0.00%
ADAR1 Capital Management, LLC42,6800.91%$1.01MNew0.05%
Braidwell LP22,4130.48%$531.86KNew0.02%
Citadel Advisors LLC8,5420.18%$202.71K+5,9330.00%
Geode Capital Management, LLC6,5500.14%$155.47K−5,5280.00%
Vanguard Capital Management LLC4,4160.09%$104.80K+2,1110.00%
Rangeley Capital, LLC3,4730.07%$82.41KNew0.08%
Hrt Financial LP3,1510.07%$74.00KNew0.00%
BlackRock, Inc.2,4000.05%$56.94K–0.00%
Dimensional Fund Advisors LP1,6750.04%$39.75KNew0.00%
Vanguard Fiduciary Trust Co1,0500.02%$24.93K–0.00%
UBS Group AG4480.01%$10.63K−370.00%
Tower Research Capital LLC (TRC)2640.01%$6.27KNew0.00%
Group One Trading, L.P.270.00%$651–0.00%
Osaic Holdings, Inc.190.00%$440–0.00%
Activest Wealth Management140.00%$339–0.00%
Barclays PLC120.00%$295New0.00%
WHI TRUST Co LLC100.00%$244–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026211M15.1%9 / 32 / 51M0M
Q1 2026170M0.5%5 / 21 / 60M0M
Q4 2025190M0.9%4 / 53 / 20M0M
Q3 2025170M0.8%3 / 23 / 30M0M
Q2 2025170M1.1%1 / 34 / 20M0M
Q1 2025180M1.1%0 / 22 / 10M0M
Q4 2024190M1.2%6 / 23 / 20M0M
Q3 2024150M3.2%2 / 14 / 30M0M
Q2 2024170M3.2%3 / 43 / 10M0M
Q1 2024150M3.3%1 / 51 / 10M0M
Q4 2023150M3.3%0 / 54 / 20M0M
Q3 2023170M3.3%2 / 34 / 30M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jonathan ViolinSee Remarks, Director207,4004.43%Sep 10, 2026
Regina Margaret GraulSee Remarks, Director156,1523.34%Aug 18, 2026
Matthew James LeoniChief Medical Officer––Sep 10, 2026
Mark J. VignolaChief Financial Officer––Sep 10, 2026
Rhonda M. ChickoChief Financial Officer25,0180.53%Aug 18, 2026
Michelle Patricia PerniceDirector––Sep 10, 2026
Nimish P. ShahDirector4,549,58597.19%Sep 10, 2026
Andrew GottesdienerDirector––Sep 10, 2026
Healthcare Co-Invest VI L.P. FairmountDirector, 10% owner––Sep 10, 2026
Healthcare Fund II L.P. FairmountDirector, 10% owner9,103,729194.47%Sep 10, 2026
Tomas KiselakDirector, 10% owner––Sep 10, 2026
Funds Management LLC FairmountDirector, 10% owner––Sep 10, 2026
Peter Evan HarwinDirector, 10% owner––Sep 10, 2026
Heidi HensonDirector––Sep 10, 2026
Peter M. HechtDirector, 10% owner910,31219.45%Jul 20, 2026
Michael J. HigginsDirector30,7400.66%Mar 27, 2025
Path Capital LP Slate10% owner6,196,063132.36%Nov 25, 2024
David Gerald Greenspan10% owner0–Nov 25, 2024

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Rhonda M. Chicko
Chief Financial Officer
Aug 14, 2026Option exercise+25,000$2.36$59.00K25,018
Regina Margaret Graul
See Remarks, Director
Aug 14, 2026Option exercise+55,849$3.30$184.30K156,152
Regina Margaret Graul
See Remarks, Director
Aug 14, 2026Tax withholding−48,629$3.79$184.30K107,523
Peter M. Hecht
Director, 10% owner
Jul 16, 2026Conversion+351,037––910,240
Michael J. Higgins
Director
Mar 25, 2025Award+9,090$2.75$25.00K30,740
Peter M. Hecht
Director, 10% owner
Mar 25, 2025Award+181,818$2.75$500.00K559,203
David Gerald Greenspan
10% owner
Nov 21, 2024Sale−357,880$1.55$554.71K0
Regina Margaret Graul
President
Jan 1, 2024Award+50,000––100,303
Peter M. Hecht
Director, 10% owner
Jan 1, 2024Award+15,000––377,385
Peter M. Hecht
Director, 10% owner
Dec 1, 2023Award+15,000––362,385
Terrance McGuire
Director
Nov 30, 2023Award+5,000––5,552
Peter M. Hecht
Director, 10% owner
Nov 30, 2023Award+20,000––347,385
Errol B. Desouza
Director
Nov 30, 2023Award+20,000––50,000
Errol B. Desouza
Director
Nov 30, 2023Award+30,000––30,000
Steven Hyman
Director
Nov 30, 2023Award+20,000––20,000
Terrance McGuire
Director
Aug 9, 2023Sale−8$3.40$270
Peter M. Hecht
Chief Executive Officer, Director, 10% owner
May 19, 2023Award+225,000$8.68$1.95M327,385
Peter M. Hecht
Chief Executive Officer, Director
Jun 3, 2021Buy+823,170$3.28$2.70M2,047,698
David Gerald Greenspan
10% owner
Jun 3, 2021Buy+961,538$3.12$3.00M7,157,601
Terrance McGuire
Director
Jun 3, 2021Buy+3,322$3.12$10.36K24,957
Terrance McGuire
Director
Jun 3, 2021Buy+92,831$3.12$289.63K697,313
Peter M. Hecht
Chief Executive Officer, Director
May 6, 2021Buy+302,000$2.43$733.86K1,224,528
Peter M. Hecht
Chief Executive Officer, Director
May 5, 2021Buy+398,001$2.53$1.01M922,528
Peter M. Hecht
Chief Executive Officer, Director
May 4, 2021Buy+300,000$2.29$687.00K524,527
Christopher I. Wright
Chief Medical Officer
Feb 25, 2021Sale(10b5-1 plan)−2,637$3.99$10.52K42,728
Anjeza Gjino
Chief Financial Officer
Feb 25, 2021Sale(10b5-1 plan)−1,824$4.00$7.30K31,599
Mark G. Currie
President and CSO
Dec 28, 2020Sale−20,107$3.01$60.52K251,648
Andreas Busch
Chief Innovation Officer
Nov 9, 2020Buy+125,000$2.53$316.25K254,704
William Huyett
Chief Financial Officer
Nov 6, 2020Sale(10b5-1 plan)−3,827$2.52$9.64K67,590
William Huyett
Chief Financial Officer
Feb 21, 2020Sale(10b5-1 plan)−3,559$5.12$18.22K71,417
Mark G. Currie
President
Dec 30, 2019Sale−25,000$2.48$62.00K271,755
Mark G. Currie
President
Dec 27, 2019Sale−25,000$2.55$63.75K296,755
Andreas Busch
Chief Innovation Officer
Nov 15, 2019Buy+125,000$1.82$227.50K125,000
William Huyett
Chief Financial Officer
Nov 8, 2019Sale(10b5-1 plan)−3,922$2.05$8.04K74,976
Peter M. Hecht
Chief Executive Officer, Director
Jul 10, 2019Option exercise+2,000$6.04$12.08K225,192
Amy W. Schulman
Director
Apr 8, 2019Buy+604,482$16.00$9.67M604,482
Amy W. Schulman
Director
Apr 8, 2019Buy+21,635$16.00$346.16K21,635
Terrance McGuire
Director
Apr 8, 2019Buy+21,635$16.00$346.16K21,635
Terrance McGuire
Director
Apr 8, 2019Buy+604,482$16.00$9.67M604,482
Mark G. Currie
President
Apr 2, 2019Buy+270,107$14.81$4.00M321,755
Peter M. Hecht
Chief Executive Officer, Director
Apr 1, 2019Award+221,736––221,736
William Huyett
Chief Financial Officer
Apr 1, 2019Award+38,320––38,320
William Huyett
Chief Financial Officer
Apr 1, 2019Award+39,172––78,898
George H. Conrades
Director
Apr 1, 2019Award+2,421––4,334
Marsha Fanucci
Director
Apr 1, 2019Award+13,671––13,671
Marsha Fanucci
Director
Apr 1, 2019Award+3,279––16,950
Mark G. Currie
President
Apr 1, 2019Award+51,648––51,648
William Huyett
Chief Financial Officer
Apr 1, 2019Award+39,179––78,912
William Huyett
Chief Financial Officer
Apr 1, 2019Award+38,327––38,327
Kevin Churchwell
Director
Apr 1, 2019Award+2,421––2,421
Amy W. Schulman
Director
Apr 1, 2019Award+3,279––7,508
Amy W. Schulman
Director
Apr 1, 2019Award+4,229––4,229
Ole Isacson
Director
Apr 1, 2019Award+2,421––2,421
George H. Conrades
Director
Apr 1, 2019Award+2,421––2,421
Stephanie Lovell
Director
Apr 1, 2019Award+2,421––2,421
Terrance McGuire
Director
Apr 1, 2019Award+7,768––7,768
Terrance McGuire
Director
Apr 1, 2019Award+3,279––3,279
Terrance McGuire
Director
Apr 1, 2019Award+162––162
Terrance McGuire
Director
Apr 1, 2019Award+6,911––6,911
Peter M. Hecht
Chief Executive Officer, Director
Apr 1, 2019Award+485––485

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
3.58%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+603.1%
From 0M shares
Short volume, 20 days
32.9%
Of volume reported to FINRA

Shares sold short, last 2 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Korsana Biosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 26,971 shares on Sep 9, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Michael J. Higgins
Director
Oct 22, 20261,107$35.42KOct 22, 2026Restricted Stock
Errol B De Souza
Director
Sep 23, 20264,903$171.56KSep 23, 2026Restricted Stock
Errol B De Souza
Director
Sep 22, 2026100$3.50KSep 22, 2026Restricted Stock
Errol B De Souza
Director
Sep 18, 20262,139$74.84KSep 18, 2026Restricted Stock

See a number that looks wrong?